Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somatostatin and brimonidine for diabetic retinopathy
NCT01726075Phase 3Completed
- Sponsor
- BCN Peptides
- Start
- Feb 2013
- Primary completion
- Nov 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in diabetic retinopathy (DR) comparing Somatostatin, Brimonidine and Placebo (3 arms). Primary endpoint: Implicit Time assessed by multifocal Electroretinogram at 24 months. Started Feb 2013; status: completed.
02
Drugs
somatostatinbrimonidine
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT01726075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01726075.